VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

IDEXX Laboratories Executive Compensation (FY25)

IDXX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Jonathan Mazelsky
Median of the other named officers
$3,944,534
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 12, 2026
Chief executive pay ratio
◇
To the median employee
Free for 3 days · no card

See how IDEXX Laboratories’s pay stands against its peers

  • IDEXX Laboratories's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Where IDEXX Laboratories sits against its disclosed peer group, with custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IDXXSee the plan and pricing
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
411 figures on this page: 400 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jonathan Mazelsky: $13,007,051 → $14,580,122 (12.1% higher)
Say-on-pay support: 93.5% → 94.2% (0.7 points higher)
CEO pay ratio: 207:1 → 218:1 (5.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is IDEXX Laboratories' chief executive and what were they paid?
Jonathan Mazelsky was paid $14,580,122 in total compensation as President and Chief Executive Officer for fiscal 2025. Mazelsky's total was 12.1% higher than the $13,007,051 reported for fiscal 2024.
What was IDEXX Laboratories' say-on-pay result?
Shareholders supported the say-on-pay proposal with 94.2% of votes cast for or against in favor at the meeting held May 12, 2026 for fiscal 2025.
Which companies are in IDEXX Laboratories' peer group?
The disclosed peer group names Agilent Technologies, Inc., Align Technology, Inc., Bio-Rad Laboratories, Inc., DexCom, Inc. and Edwards Lifesciences Corporation, among others.
What is IDEXX Laboratories' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 218:1, against median employee compensation of $66,956.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jonathan Mazelsky
President and Chief Executive Officer
◇—◇◇◇—◇◇
Brian McKeon
Executive Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Michael Lane
Executive Vice President and General Manager, Global Reference Laboratories and Information Technology
◇—◇◇◇—◇◇
James Polewaczyk
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Tina Hunt
Executive Vice President, Strategy, Sector Development and Global Operations
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jonathan Mazelsky
President and Chief Executive Officer
◇—◇◇◇—◇◇
Brian McKeon
Executive Vice President, Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Tina Hunt
Executive Vice President, Strategy, Sector Development and Global Operations
◇—◇◇◇—◇◇
Michael Lane
Executive Vice President and General Manager, Global Reference Laboratories and Information Technology
◇—◇◇◇—◇◇
James Polewaczyk
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jonathan Mazelsky
President and Chief Executive Officer
◇—◇◇◇—◇◇
Brian McKeon
Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer)
◇—◇◇◇—◇◇
Tina Hunt
Executive Vice President, Global Strategy and Commercial
◇—◇◇◇—◇◇
Michael Lane
Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology
◇—◇◇◇—◇◇
Martin Smith
Executive Vice President, Global Operations and R&D
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jonathan Mazelsky
President and Chief Executive Officer
◇—◇◇◇—◇◇
Michael Lane
Executive Vice President and General Manager, CAG Diagnostics Business Unit
◇—◇◇◇—◇◇
Tina Hunt
Executive Vice President, Global Strategy and Commercial
◇—◇◇◇—◇◇
Martin Smith
Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security
◇—◇◇◇—◇◇
Andrew Emerson
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Brian McKeon
Former Executive Vice President, Chief Financial Officer and Treasurer
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew EmersonRSU◇——◇——◇
Andrew EmersonPSU◇◇◇—◇—◇
Andrew EmersonOPTION◇——◇—◇◇
Jonathan J. MazelskyPSU◇◇◇—◇—◇
Jonathan J. MazelskyOPTION◇——◇—◇◇
Martin SmithRSU◇——◇——◇
Martin SmithPSU◇◇◇—◇—◇
Martin SmithOPTION◇——◇—◇◇
Michael J. LaneRSU◇——◇——◇
Michael J. LanePSU◇◇◇—◇—◇
Michael J. LaneOPTION◇——◇—◇◇
Tina HuntPSU◇◇◇—◇—◇
Tina HuntOPTION◇——◇—◇◇
Tina HuntRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Tina HuntOption——◇February 13, 2031
PSU◇◇——
Option◇—◇February 13, 2034
RSU◇◇——
RSU◇◇——
Option◇—◇2/7/2033
Option◇—◇February 13, 2032
Option◇—◇2/12/2035
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Michael LaneRSU◇◇——
RSU◇◇——
RSU◇◇——
Option——◇February 13, 2031
Option——◇February 13, 2029
PSU◇◇——
Option◇—◇February 13, 2034
RSU◇◇——
Option◇—◇2/7/2033
Option◇—◇February 13, 2032
Option◇—◇2/12/2035
PSU◇◇——
Martin SmithOption◇—◇2/12/2035
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option——◇August 31, 2031
PSU◇◇——
Option◇—◇February 13, 2034
RSU◇◇——
Option◇—◇2/7/2033
RSU◇◇——
Option◇—◇February 13, 2032
Jonathan MazelskyOption——◇February 13, 2031
Option——◇February 13, 2031
Option——◇February 13, 2030
Option——◇November 3, 2029
Option——◇August 4, 2029
Option——◇February 13, 2029
Option——◇February 13, 2028
Option——◇February 13, 2027
RSU◇◇——
Option◇—◇2/12/2035
RSU◇◇——
Option◇—◇February 13, 2034
Option◇—◇2/7/2033
RSU◇◇——
Option◇—◇February 7, 2033
Option◇—◇February 13, 2032
RSU◇◇——
Option◇—◇February 13, 2032
Brian McKeonOption——◇February 13, 2031
PSU◇◇——
RSU◇◇——
Option◇—◇February 13, 2034
RSU◇◇——
Option◇—◇2/7/2033
RSU◇◇——
Option◇—◇February 13, 2032
Andrew EmersonOption——◇February 13, 2031
Option——◇February 13, 2030
Option——◇February 13, 2029
Option——◇February 13, 2028
PSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
PSU◇◇——
RSU◇◇——
Option◇—◇February 13, 2034
RSU◇◇——
Option◇—◇2/7/2033
RSU◇◇——
Option◇—◇February 13, 2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Lawrence D. Kingsley
Board chair · Lead independent director
◇◇◇———◇
M. Anne Szostak
◇◇◇———◇
Irene Chang Britt
◇◇◇———◇
Daniel M. Junius
◇◇◇———◇
Stuart M. Essig, PhD
◇◇◇———◇
Bruce L. Claflin
◇◇◇———◇
Sam Samad
◇◇◇———◇
Sophie V. Vandebroek, PhD
◇◇◇———◇
Joseph L. (Jay) Hooley
◇◇◇———◇
Karen Peacock
◇◇◇———◇
Asha S. Collins, PhD
◇—————◇
Jonathan J. Mazelsky served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Align Technology, Inc. ALGN
  • Bio-Rad Laboratories, Inc. BIO
  • DexCom, Inc. DXCM
  • Edwards Lifesciences Corporation EW
  • Elanco Animal Health Incorporated ELAN
  • Hologic, Inc. HOLX
  • Illumina, Inc. ILMN
  • Intuitive Surgical, Inc. ISRG
  • Mettler-Toledo International Inc. MTD
  • ResMed Inc. RMD
  • Revvity, Inc. RVTY
  • STERIS plc STE
  • The Cooper Companies, Inc. COO
  • Waters Corporation WAT
  • Zoetis Inc. ZTS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 12, 2026=◇◇◇
2024May 7, 2025=◇◇◇
2023May 6, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 11, 2022=◇◇◇
2020May 12, 2021=◇◇◇
2019May 6, 2020=◇◇◇
2018May 8, 2019=◇◇◇
2017May 9, 2018=◇◇◇
2016May 3, 2017=◇◇◇
2015May 4, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Tell me when IDEXX Laboratories files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact IDEXX Laboratories disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where IDEXX Laboratories sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether IDEXX Laboratories' disclosed peer group is defensible, who names IDEXX Laboratories back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
411 figures on this page: 400 cited to the filing that reported them, 11 calculated from figures it prints.
400 cited to the filing
11 calculated from the filing

Documents cited

  1. 0000874716-26-000110
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000874716-26-000064
    2025 Non-Employee Director Compensation Table · 2025 Outstanding Equity Awards at 2025 Fiscal Year-End · CEO Pay Ratio · Non-Employee Director Compensation · and 1 more section
  3. 0000874716-25-000085
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000874716-25-000054
    Executive Compensation Tables
  5. 0000874716-24-000107
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000874716-24-000075
    Executive Compensation Tables
  7. 0000874716-23-000074
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000874716-22-000023
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000874716-21-000038
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001564590-20-024269
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0000874716-19-000019
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001144204-18-028832
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001144204-17-024774
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-16-582014
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “IDEXX Laboratories executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/IDXX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about IDEXX Laboratories and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

Biopharma & Life Sciences rankings

Peers IDEXX Laboratories discloses

The companies named in IDXX's own disclosed peer group.

Terms on this page

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}